Market Intelligence, Clinical Progress, and High-Purity Reagents for Colorectal Cancer Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LY6G6D drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LY6G6D ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View LY6G6D Products |
| Gene Delivery | LY6G6D Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based binding assays. |
View LY6G6D Products |
| Benchmark Ab | Anti-LY6G6D Benchmark Antibody Recombinant monoclonal positive control for assay validation. |
View LY6G6D Products |
| Validator | LY6G6D siRNA Set For target knockdown verification and specificity profiling. |
View LY6G6D Products |
| Related Target A | CEA (Carcinoembryonic Antigen) Synergistic colorectal cancer-associated antigen for combination or bispecific targeting. |
View CEA Products |
| Related Target B | GPA33 (Glycoprotein A33) Colorectal-restricted lineage marker used in comparative specificity and targeting assays. |
View GPA33 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus LY6G6D ortholog proteins available with >95% purity |
| Subfamily counter-screening (LY6 family off-targets) | Homolog panel proteins (LY6E, LY6K, LY6H) strictly verified by mass spectrometry and sequence analysis |
| Lack of positive control antibodies | Sequence-verified clinical benchmark antibodies available as reference controls |
| Target validation false positives | Sequence-verified siRNA sets included for functional knockdown validation |
Live LY6G6D R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LY6G6D therapeutics is intensifying, with major players shifting focus from traditional mAbs to T-cell engagers (TCEs) and Antibody-Drug Conjugates (ADCs). As first-generation therapies reach the clinic, the next wave of R&D is targeting highly specific epitopes to avoid cross-reactivity with other LY6 family members and optimizing internalization kinetics for payload delivery.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Bispecific T-Cell Engager (TCE) | Roche, Amgen | Colorectal Cancer (CRC) | Affinity optimization & cross-species binding (Need high-purity Cyno/Human ECD proteins) |
| Antibody-Drug Conjugate (ADC) | Innate Pharma, Daiichi Sankyo | Solid Tumors, CRC | Internalization validation (Need stable cell line generation via Lentivirus) |
| CAR-T / Cell Therapy | Academic Institutions, Biotech Startups | Refractory Colorectal Cancer | In vitro killing assays (Need stable overexpression cell lines and target verification) |